arrow
M

Menelaos Papoutselis

Democritus University of Thrace
H指数:10
被引数:465

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hans-Based Cell of Origin Is Not of Prognostic Significance in Diffuse Large B-Cell Lymphoma Patients: A Retrospective Single-Center Study Conducted in 326 RCHOP-Treated Patients

Hans-Based Cell of Origin 在弥漫大B细胞淋巴瘤患者中无预后意义:一项在326例接受RCHOP治疗的患者的单中心回顾性研究

2025-12-010
PRE
A ROLE FOR ADAR1 IN THE RESISTANCE TO HYPOMETHYLATING AGENTS (HMA) IN HIGH-RISK MYELODYSPLASTIC SYNDROME (HR-MDS)

ADAR1在对抗低甲基化剂(HMA)方面的高危骨髓增生异常综合征(HR-MDS)中的作用

2025-09-010
PRE
THE ROLE OF THE ADENOSINERGIC PATHWAY IN THE RESPONSE TO AZACYTIDINE IN HR-MDS PATIENTS PROGNOSIS-PREDICTIVE FACTORS OF RESPONSE TO TREATMENT

腺苷能通路在AZACYTIDINE对HR-MDS患者反应中的作用——治疗反应的预后预测因素

2025-09-010
PRE
Ravulizumab stabilizes life-threating intravascular hemolysis following delayed hemolytic transfusion reaction due to alloantibodies anti-e and anti-Jka: the first successful administration

拉瓦鲁zumab(Ravulizumab)能够稳定由抗-e和抗-Jka同种抗体引起的延迟性溶血性输血反应后的危及生命血管内溶血:首次成功给药。

2025-08-280
OAAI
Lenalidomide Efficacy in Patients with MDS and Del-5q: Real-World Data from the Hellenic (Greek) National Myelodysplastic & Hypoplastic Syndromes Registry (EAKMYS)

来那度胺在伴del-5q的骨髓增生异常综合征患者中的疗效:来自希腊骨髓增生异常与低增生性综合征登记研究(EAKMYS)的真实世界数据

CANCERS
IF4.4
2025-04-220
OA
Myelodysplastic neoplasm with isolated thrombocytopenia and immune thrombocytopenic purpura in adults: insights from a comparison of two national registries
LEUKEMIA
IF13.4
2023-01-161
PRE
Refinement of prognosis and the effect of azacitidine in intermediate-risk myelodysplastic syndromes
2021-02-112
OAAI
Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
2020-12-0812
OAAI
Estimated glomerular filtration rate independently predicts outcome of azacitidine therapy in higher-risk Myelodysplastic syndromes. Results from 536 patients of the Hellenic National Registry of Myelodysplastic and Hypoplastic syndromes
2020-06-262
PREAI